Monoclonal antibodies against the presynaptic calcium channel antagonist ω-conotoxin GVI A from cone snail poison  by Tombaccini, D. et al.
Volume 261, number 1, 7 1-75 FEBS 08105 February 1990 
Monoclonal antibodies against he presynaptic alcium channel 
antagonist wconotoxin GVI A from cone snail poison 
D . Tombaccini*+, O.M. Adeyemo+, H.B. Pollard* and G. Feuerstein+O 
*Laboratory of Cell Biology and Genetics, NIDDK, National Institutes of Health, ‘Department of Neurology, Uniformed Services 
University of the Health Sciences, Bethesda, MD and “Department of Pharmacology, SK&F, Philadelphia, PA 19406, USA 
Received 21 July 1989 
Monoclonaf antibodies have been prepared against oxonotoxin GVI A, a peptide isolated from marine snails of the genus Conus ~Con~ge~ru~h~ 
a+ and Conus magus). This toxin is a blocker of select presynaptic Ca channels in the central nervous system. Antigenic o-conotoxin GVI A was 
synthesized as a covalent conjugate with bovine serum albumin and injected S.C. An ELISA assay combined with a competitive inhibition assay 
was used to select and characterize monoclonal antibodies able to recognize and bind the free toxin. Several of the antibodies were found to block 
w-conotoxin GVI A inhibition of %a transport into rat brain synaptosomes and to block w-conotoxin GVI A binding to membranes from the 
same preparation, The antibodies recognize native, synthetic toxin, and are useful for analysis of toxin in biological fluids. 
Conotoxin; Calcium; Mon~lon~, Channek P~s~aptic; Transport 
1. INTRQDUCTION ing behavioral effects in rats subjected to intracerebro- 
ventricular admi~stration of the toxin 1101. 
o-Conotoxin GVI A (w-&x GVI A) is a bicyclic 27 
amino acid peptide isolated from the marine snail, 
Conus geographus and Conus magus [ 1,2], which inac- 
tivates select presynaptic alcium channels in the central 
nervous system [3-61. The bicyclic structure is defined 
by disulfide bonds between 6 cysteines (see fig. 1). Other 
structurally related polypeptide toxins which are less 
well characterized also occur in these snails, including 
cu-conotoxin, a nicotinic antagonist and p-conotoxin, a 
Na+ channel antagonist [ 1,2]. w-ctx GVIA does not 
seem to have an effect on the dihydropyridine-sensitive 
Ca2’ channels at the postsynaptic level [7-91, and in- 
deed appears to bind to brain calcium channels at 
separate sites from the binding sites of verapamil or di- 
hydropyridine analogues [7,8]. However, there is 
presently no method to measure w-ctx GVI A in tissue 
extracts or biological fluids, other than biological ac- 
tivity, and there exist no specific antagonists to the w- 
ctx GVIA. This problem has thus severely limited the 
ph~macologic exploration of the molecule. Indeed, in 
recent studies on the activity of w-ctx GVI A on 
chromaffin cells [lo] and islets of Langerhans [l 11, it 
was necessary to verify w-ctx GVIA potency by measur- 
To provide a useful tool for the study of the physiolo- 
gy of these Ca2’ channels in the nervous system, we 
have now prepared monoclonal antibodies against the 
w-ctx GVIA molecule. In this report we describe the 
procedures required to synthesize an immunogenic 
form of w-&x GVI A [ 12,131, and the method for suc- 
cessful production of monoclonal antibodies to the free 
toxin. These antibodies do not exhibit cross-reactivity 
with other toxic peptides with related chemical struc- 
tures. In at least one instance synthetic w-ctx GVIA has 
been shown to be equally toxic to authentic native toxin 
I141. 
2. MATERIALS AND METHODS 
2.1. Preparation of itnmunogen 
Synthetic w-ctx GVIA (Peninsula Lab. Inc., Belmont, CA) 
(0.5 mg) solubilized in 100~1 of dimethylformamide (Sigma 
Chemical Co., St. Louis, MO) was added with stirring to a solution 
containing 1 .O mg of bovine serum aibumin (BSA) (Sigma Chemical 
(N)NH2- C-K-S-Hy-G-S-S-C-S-HY-T-S-Y 
5 r- 
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Fig.1. Structure of w-cm GVIA. The letters are the usual one Setter 
codes for the 20 amino acids. Hy is hydroxyproline. Heavy lines be- 
tween C (cysteine) residues represent disulfide bonds. Data are from 
the literature 111. 
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Co., St. Louis, MO) and 2.5 mg of EDC (1-ethyl-3,3’-dimethyl- 
amino-propyl-carbodiimide, Sigma Chemical Co., St. Louis, MO) in 
3 ml of distilled water. The reaction was stirred at room temperature 
for 18 h and pH maintained at 5.5. The conjugated toxin was dialyzed 
through a Spectrapor dialysis membrane with a molecular weight 
cutoff of 3500 against distilled water for 72 h and then lyophilized 
1151. 
2.2. Mice and immunization 
Mice used in this study were Balb/c female (NIH stock). Mice (age 
6-10 weeks) were immunized by injecting with 100 fig immunogen re- 
suspended in 0.9% in NaCl, emulsified in complete Freunds adjuvant 
[16] (ratio 1: l), and injected subcutaneously. Three weeks later the 
animals received 5Opg of immunogen emulsified in incomplete 
Freunds adjuvant, and a booster injection with 50 gg immunogen re- 
suspended in a saline solution 4 days prior to fusion. 
2.3. Myeloma cell line 
The myeloma cell line used was P3-NSI-I-Ag4-1, and was routinely 
maintained in tissue culture flasks in Dulbecco Modified Eagles 
Minimal Essential Medium (DMEM) containing 10% fetal calf serum 
(FCS) (Biofluids Inc., Rockville, MD). 
2.4. Cell fusion technique 
The spleens from immunized mice were aseptically removed and 
single cell suspensions were prepared. Spleen lymphocytes were fused 
with mouse myeloma cells (ratio 5 : 1, lymphocytes : myeloma) in the 
presence of polyethylene glycol (M.W. 1000) (Sigma Chem. Co., St. 
Louis, MO) according to the method of Kohler and Milstein [17]. 
Following three washes in FCS-free medium, the cells so produced 
were then resuspended in DMEM containing HAT (hypoxanthine, 
10e4 M; aminopterin, lo-’ M; and thymidine, 4 x 10e5 M) and 10% 
FCS. 
The cells were then plated out into ten 24 well plates which were in- 
cubated at 37°C in an humidified incubator containing 10% COz. 
The fused cells were fed with the same HAT medium 5 days after 
plating and the colonies were observed to be growing between days 12 
and 15 [12]. Wells with a growth of cells were screened for specific im- 
munoglobulin content using an ELISA assay [18-201. 
2.5. Enzyme-linked immunosorbent assay 
To select hybridoma producing specific immunoglobulins (IgGs), 
supernatants were tested in parallel against he free w-ctx GVIA, the 
BSA-conjugated toxin and BSA alone. Assays were carried out in 96 
well flat bottom, white polystyrene Dynatech microfluor plates 
(Dynatech Laboratories Inc., Alexandria, VA). The plates were 
prepared as follows: a 1OOJ aliquot of a solution of phosphate- 
buffered saline pH 7.4 containing free w-ctx GVIA, or BSA- 
conjugated w-ctx, or BSA at a concentration of 10 pg/ml was added 
to all wells on the plate. After incubation overnight, the plates were 
washed three times with PBS containing 0.05% Tween20. The plates 
were then blocked in 5% dry fat-free milk in PBS for 2 h at 37°C. 
100,ul of the hybridoma supernatants were mixed with 0.01% 
Tween20 and added to wells in a volume of 100/r! and incubated at 
37°C for 2 h. They were then washed as above with PBS-Tween20 
before addition of 100 ~1 of &galactosidase-conjugated sheep anti 
mouse IgGF(ab)Z fragment (Amersham Lab.) diluted in PBS- 
Tween20 (1:250). The plates were then incubated for an additional 
2 h at 37°C. 100 pl of a solution in PBS of the fluorogenic substrate 
4-methylumbelliferyl-fl-galactopyranoside was added to each well. 
Fluorescence was read in a Dynatech Microfluor reader 30 min after 
the addition of the substrate. Wells were considered positive when the 
fluorescent units were more than 1800 fluorescent units greater than 
the negative control (full scale = 4000). 
2.6. Competitive inhibition assay 
Competitive inhibition assays were carried out in 96 well flat- 
bottom, white polystyrene Dynatech microfluor plates, as described 
above 12 1,221. 
12 
The plates were prepared as follows: 100 ,ul of a solution of 0.1 M 
carbonate/bicarbonate buffer pH 8.6 containing w-ctx GVIA at a 
concentration of lO,ug/ml was added to all wells on the plate. The 
plates were incubated for 2 h at 37”C, the non-adsorbed W-ctx GVI A 
removed and the wells washed with PBS/TweenZO as described 
above. An initial experiment was performed to determine the concen- 
tration of anti-toxin IgG that bound approximately 50% of the avail- 
able sites on the solid phase-bound w-ctx GVIA. The monoclonal 
IgGs were diluted to this concentration (50 fig/ml in PBS/Tween20) 
for the competitive inhibition assay. Aliquots of 100 pl of serial log 
diluted toxin were then mixed with 100 pl of aliquots of monoclonal 
IgGs and incubated for 2 h at 4°C. Aliquots of 100 ~1 of these mix- 
tures were added to w-ctx GVI A-coated microtiter plates and in- 
cubated for 2 h at 37°C. 
Toxin-coated wells incubated with monoclonal IgGs alone served as 
the non-inhibited positive controls, while wells coated with BSA only 
incubated with monoclonal IgGs were controls for nonspecific bind- 
ing of monoclonal antibody. After incubation the plates were washed 
with PBS-Tween, as above, and detection of toxin-antibody reaction 
was determined with fluorogenic substrate 4-methylumbe1liferyl-fl- 
galactopyranoside as described above. 
2.7. Subcloning 
The clones with the highest reading over the control were selected 
for subcloning performed by the standard procedure of limiting dilu- 
tion (161. 
2.8. Immunoglobulin purification and subclass identification 
Monoclonal immunoglobulin was concentrated from culture 
medium using microporous membranes on a Minitan Ultrafiltration 
System (Millipore Co., Bedford, MA) and then purified on a Protein- 
A-Sepharose column (Pierce Chemical Co., Rockport, IL) [23,24]. 
Monoclonal immunoglobulins were lyophilized and stored at - 20°C. 
Immunoglobulin subclass was determined by enzyme immunoassay 
kit for isotyping mouse monoclonal antibody provided by Zymed 
(Zymed Lab. Inc., San Francisco, CA). 
3. RESULTS 
3.1. Preparation of monoclonal ntibodies 
Small toxic molecules uch as w-conotoxin GVIA are 
notoriously difficult to use as antigens, and in prelimi- 
nary studies we attempted to use the in vitro technique 
[ 181. This method was unsuccessful, and we resorted to 
construction of a BSA-w-ctx GVIA adduct and conven- 
tional in vivo methods. We chose BSA because it yields 
soluble conjugates, does not elicit significant produc- 
tion of antibody, and its reactivity is well known and 
predictable [12,131. To form the adduct we used carbo- 
diimide, since w-ctx GVIA has a free amino terminal, 
suitable for forming amide linkages with carboxyl resi- 
dues on BSA. We also enhanced the immunogenicity of 
the toxin-BSA conjugate by emulsifying in Freunds ad- 
juvant prior to immunization. 
The results of the successful fusion that yielded the 
monoclonal antibodies we describe in this report are 
summarized in table 1. As summarized, the ensuing suc- 
cessful fusion produced a high number of fused cells 
(337) compared to number of wells seeded (456). In our 
initial ELISA screening assay we tested supernatants 
for antibodies that recognize free w-ctx GVI A or the w- 
ctx GVIA-BSA conjugate. Of the 337 growing hy- 
bridomas, 26 were positive, with a specific efficiency of 
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Table 1 
Production of monoclonal antibodies positive for reactivity of W-ctx 
GVIA 
Number of welfs seeded 456 
Number of wells with growth 331 
Seeded wells with growth (%) 73 
Number of positive culture supernatants detected by ELBA 26 
Specific efficiency 7.7 
Number of positive culture supernatants detected by 
competitive inhibition assay 3 
7.7%. We also tested the specificity of the 26 hy- 
bridoma producing antibodies for w-ctx GVIA binding 
by examining their reactivity to unconjugated toxin 
peptides with related structure. cu-Conotoxin Ml and LY- 
conotoxin Gl are two toxic peptides also found in the 
crude venom which are blockers of nicotinic receptors 
but which are homologous to w-ctx GVI A. They have 
only 13 amino acids each, and only two disulfide 
bridges, rather than the three found in w-conotoxin 
GVI A [ 11. No reactivity of the 26 hybridoma super- 
natants was found against either the cu-conotoxins Gl 
or Ml when both peptides were tested in their free state. 
3.2. ~~e~o~~~~t of a competitive ~nhibiiion assay for 
w-ctx GVIA 
To use the monoclonal antibodies for quantitative 
analysis we attempted to develop a competitive inhibi- 
tion enzyme immunoassay. The principle of the method 
is to measure the ability of free toxin to inhibit binding 
of antitoxin antibody to solid phase-bound w-ctx 
GVIA, under conditions of a non-saturating concentra- 
tion of affinity purified antibody. As shown in fig.2, we 
incubated various dilutions of affinity purified mono- 
clonal IgGs in wells coated with lOpgfm1 of w-ctx 
GVIA, IgG concentration above 500 pglml saturated 
the binding sites, but below this concentration the curve 
was linear to 1 pug/ml of antibody. We therefore used a 
concentration of 50 ,ug/ml of monoclonal IgG in the re- 
mainder of experiments for development of the com- 
petitive inhibition assay. As shown in fig.3, the binding 
of anti-w-ctx GVI A antibody to w-ctx GVI A can be in- 
hibited in a dose-dependent manner by free w-ctx 
GVIA. The curve is linear between 1.0 x lOA M to 
1.0 x 10-s M, allowing the quantification of toxin in 
test samples over a 4 log range. The maximum sensitivi- 
ty of the competitive inhibition assay is defined by the 
lowest toxin concentration that falls in the range of 
linear inhibition. By this method, however, only 3 of 
the original 26 hybridoma supernatants positive by the 
ELISA were found suitable. 
3.3. Evidence that antibodies detect native structure of 
#-conotoxin GVIA 
The successful competitive assay also allowed us to 
examine structural features of the native w-ctx GVIA 
f L f 
1 10 100 1000 
IgGs, pglml 
Fig.2. Titration curve for the binding of two different affinity 
purified monoclonal antibodies anti-w-ctx GVIA to solid phase- 
bound unconjugated w-ctx GVI A. The data are pooled from three ex- 
periments with four replicates for each point. SE was less than 10% 
of the mean in all cases. 
detected by various antibodies, and to further test the 
possible reactivity of the cu-conotoxin homologues. (J- 
ctx GVIA was boiIed in PBS for 10 min, and tested for 
reactivity in the competitive assay. As shown in fig.3, it 
was inactive even at 10m5 M. We also reduced and 
alkylated the toxin with DTT and iodoacetamide. After 
reducing excess iodoacetamide with DTT we found the 
resulting toxin inactive in the competition assay (see 
fig.3). We concluded that our anti-w-ctx GVIA anti- 
bodies recognize exclusively the native form of the 
toxin. 
3.4. Detection of toxin in biological samples 
A valuable attribute for specific antibodies is the 
ability to detect an antigen in biological samples. We 
therefore added u-ctx GVIA to human serum, and 
tested for the toxin directly. As shown in fig.3, recovery 
in the concentration range of 1O-5-1O-8 M was nearly 
that of buffer alone. Less was recovered at lower con- 
centrations. 
We observed that w-conotoxin GVIA is quite toxic to 
the goldfish (Carassius aura&s). We therefore injected 
toxic doses of toxin i.p. into goldfish, and froze the in- 
dividual fish when evidence of intoxication occurred. 
Such evidence included loss of balance and subsequent 
death, in a period dependent on the dose of toxin. The 
fish were homogenized in ice-cold PBS, particulate 
material spun down at 20000 x g for 30 min, and the 
supernatant solution assayed for w-ctx GVIA, 
Recovery from intoxicated fish (range l-100 nmol of w- 
ctx GVIA) was 2 80%. 
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w-CONOTOXIN GYIA, M 
Fig.3. Inhibition of binding of affinity purified monoclonal antibody 
to solid pha~-Lund w-ctx GVI A by various ~on~entra~ons of free 
w-ctx GVI A diluted in PBS (C+-O) or in fetal calf serum (t---e). 
(A---+ and (A--&) represent the inhibition of binding of anti-w-&x 
GVIA~ti~y too_ctxGVIA byff~onoto~nsG1 andEAl. (n----n) 
represents inhibition of binding of anti+ctx GVI A antibody by boil- 
ed and alkylated w-ctx GVIA. Bach point is the mean of eight 
replicates. The standard error was less than 10% of the mean. 
o-ctx GVIA elicits profound behaviors changes 
when instilled into rat brain, i.c.v. [1], and [*251]w-ctx 
GVI A binds specifically to regions of rat brain [25]. We 
found that preincubation of low6 M [r2’I]w-ctx GVIA 
with anti-w-&r GVIA monoclonal antibody for 30 min 
at 4’C blocked toxin binding to rat brain synaptosomes 
(data not shown). 
4. DISCUSSIGN 
In the present study we show that monoclonal anti- 
bodies can be prepared against w-ctx GVIA, a specific 
blocker of presynaptic Cat+ channels in the vertebrate 
nervous system [3-51. The antibodies can detect w-ctx 
GVIA immobilized on surfaces, and in some cases can 
be used as the basis for a sensitive com~tition assay. In 
the latter case the toxin added exogenously can be 
detected in biological fluids, such as serum, or in 
aqueous extracts of biological tissue. Our preliminary 
studies have also shown that our reagents have the 
potential to be adaptable to dipstick technology, should 
detection in environmental and biological samples 
prove of value. 
All of the antibodies found suitable for the competi- 
tion assay proved specific for native toxin. While we an- 
ticipated that redu~tion/~kylation would be inimicable 
to the interaction with antibody, it was not obvious that 
boiling would profoundly denature the otherwise triple- 
disulfide-bonded w-ctx GVI A. Clearly, secondary and 
tertiary structure of the toxin is based on more than the 
constraints afforded by the disulfide bonds. These data 
provide us with an unexpected advantage, in that 
recovered activity in biological specimens represents, by 
de~nition, native molecules. The additional meaning is 
that the antigenic site for the monoclonal antibody 
must also be the site of binding of the toxin to the pre- 
synaptic calcium channel on the target membrane. 
w-ctx GVIA is similar in structure to a number of en- 
dogenous peptides. These range from endothelin [26], 
which is the most powerful hypertensive agent now 
available, to toxins such as cu-conotoxins Gl and Ml 
[l], scorpion toxin 1261, sarafotoxin 1271 and apamin 
[26]. All have sequences with less than 30 amino acids, 
and have two or three disulfide bonds. We have only 
tested the most closely related Iw-conotoxins for cross- 
reactivity. However, the lack of cross-reactivity en- 
courages us to expect that endogenous compounds yet 
to be tested or discovered, or indeed other toxins, will 
not be the basis of false positive reactions. Indeed, our 
methods may prove useful for developing immunologi- 
cal reagents with specificity for these other molecules. 
Finally, the ability of our anti-w-conotoxin GVIA 
monoclonal to inhibit binding of w-ctx GVIA to rat 
brain synaptosomes emphasizes the likelihood of using 
our reagents as antitoxins for affected organisms. For 
example, we have shown that a monoclonal antibody 
against the trichoth~ene mycoto~n T-2 is capable of 
neutr~~ing T-2 toxin in human ~-l~phoblastoid cells 
and in rats [28]. Another possible use is the production 
of anti-idiotype antibodies to our monoclonals. Such 
anti-idiotypes ought to mimic the action of the original 
toxin, and to provide ready delineation of presynaptic 
calcium channels in cells and tissues. The production of 
anti-idiotypes to this toxin will be aided by the fact that 
in mammals gophers nerves and organs lack sensitivi- 
ty to ~-conotoxin GVI A. 
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